Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2– metastatic breast cancer: a prospective, monocentric study

Background: Breast cancer is the most frequent tumour worldwide, and the HR+/HER2– subtype is the most common. For this tumour type, endocrine therapy (ET) is the mainstay of treatment. The association of ET and CDK4/6 inhibitors (CDK4/6i) represents the gold standard for first-line or second-line t...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Raffaella Palumbo, Erica Quaquarini, Giuseppe Saltalamacchia, Alberto Malovini, Pietro Lapidari, Barbara Tagliaferri, Ludovica Mollica, Cristina Maria Teragni, Chiara Barletta, Laura Deborah Locati, Federico Sottotetti
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BioExcel Publishing Ltd 2024-02-01
Ráidu:	Drugs in Context
Fáttát:	endocrine resistance metastatic breast cancer palbociclib post-progression therapeutic strategies
Liŋkkat:	https://www.drugsincontext.com/efficacy-and-activity-of-treatments-after-progression-from-palbociclib-plus-endocrine-therapy-in-patients-with-hr-her2-metastatic-breast-cancer-a-prospective-monocentric-study/
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!